Friday, 23 February, 2024

04 Oct 2012 | Press Release

news > News and Events > Page 1

Further market decline in Japan in Q3 is materially impacting revenue and profit outlook for full year 2012

Company Reporting and Announcements

Today Nobel Biocare (NOBN) announced preliminary revenue for the first nine months of EUR 427.5 million, up 3.1% in euro and down 2.4% at constant exchange rates (CER).


Revenue for the third quarter was EUR 131.0 million, up 2.2% in euro and down 5.1% at CER.

Revenue development in the third quarter continued to be in line with the market. Excluding Japan, revenue was flat (-0.1% at CER) for the quarter and modestly down 0.6% at CER year-to-date.

As communicated earlier, adverse media reporting on implant treatments has impacted patient flow in Japan. This has led to a further deterioration of the market in the course of the third quarter. Nobel Biocare has a leading market share in Japan, which represents about 13% of its revenue and contributes disproportionately high profit. The development is difficult to predict at this point in time but the company does not anticipate any improvement in the coming months.

APAC excluding Japan was up 15.8% (CER) for the quarter and 7.4% (CER) year-to-date. In EMEA revenue development was consistent with the previous quarters and in line with the market, as also in North America, where the market continued to soften.

The company will continue with its strategic investments in innovation and selling. At the same time Nobel Biocare will maintain its high cost-consciousness and drive efficiencies throughout the business. These investments are important to further build Nobel Biocare and accelerate growth in the mid-term.

Nobel Biocare foresees development of revenue for the full year in line with the market, which is anticipated to decline modestly. Based on this and barring any unforeseen events, in particular a further deterioration in Japan, Nobel Biocare expects revenue for the full year to decline in the modest single-digit percentage range at CER. The EBIT for the full year is expected to be about EUR 67 to 70 million (as reported) as a consequence of the revenue shortfall in Japan.

Revenue by region (preliminary)
in EUR million
Q3YTD
 20122011*Var**Var (CER)**9M 20129M 2011*Var**Var (CER)**
Europe, Middle East and Africa (EMEA)46.848.0-2.5%-3.7%168.0173.7-3.3%-3.9%
Share of total revenue36%37%  39%42%  
Americas54.248.212.4%0.3%167.5151.910.3%1.5%
Share of total revenue41%38%  39%37%  
Asia/Pacific30.032.0-6.2%-15.5%92.089.03.4%-6.1%
Share of total revenue23%25%  22%21%  
Total131.0128.22.2%-5.1%427.5414.63.1%-2.4%
* Prior year figures are reclassified to reflect changes in the mgmt structure ** Figures are calculated on unrounded figures

The company will provide full details of its third quarter results on the scheduled reporting date, 8 November 2012.

Related Contacts

Management

Staying Safe

Clinical

Techniques

Stream the latest dental videos...
VITA ENAMIC STAINS Shade Characterization Tutorial

Sponsored Links...

Upcoming Events...

Feb 23 2024
Feb 29 2024
Mar 06 2024
Mar 09 2024
Mar 12 2024
Mar 13 2024
Mar 13 2024
Mar 14 2024

Expodental 2024

Madrid, SPAIN

Mar 15 2024
Mar 16 2024
Mar 21 2024

ADX24 Sydney

Sydney, AUSTRALIA

Mar 22 2024
Apr 05 2024
Apr 12 2024
Apr 16 2024

Dentists Behaving 'Very' Badly

Brisbane, AUSTRALIA

Apr 19 2024
Apr 19 2024

IDEM Singapore 2024

Singapore, SINGAPORE

Apr 23 2024
Apr 24 2024
May 01 2024
May 02 2024
May 09 2024
May 11 2024
May 14 2024
May 22 2024
May 24 2024
May 29 2024
May 30 2024
May 31 2024

Scottish Dental Show 2024

Glasgow, UNITED KINGDOM

May 31 2024

Famdent Show Mumbai 2024

Mumbai, INDIA

Jun 01 2024
Jun 06 2024
Jun 09 2024
Jun 11 2024
Jun 22 2024
Jul 16 2024
Jul 25 2024
Aug 23 2024
Aug 29 2024

Practical Endodontics Workshop

Sydney, AUSTRALIA

Sep 07 2024
Sep 14 2024
Sep 26 2024
Oct 03 2024
Oct 10 2024
Oct 17 2024

ADOHTA 2024 National Congress

Sydney, AUSTRALIA

Oct 24 2024
Nov 13 2024
Nov 29 2024
Mar 25 2025

IDS 2025

Cologne, GERMANY

May 08 2025